Actively Recruiting
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
Led by Biotheus Inc. · Updated on 2024-12-19
404
Participants Needed
45
Research Sites
214 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with Paclitaxel as second-line treatment for SCLC
CONDITIONS
Official Title
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agree to participate and able to complete all study procedures
- Age 18 to 75 years
- Histologically or cytologically confirmed small cell lung cancer
- Advanced small cell lung cancer progressed or relapsed after first-line platinum chemotherapy (extensive-stage patients must have received immune checkpoint inhibitors)
- Adequate organ function
- Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1
- Life expectancy of at least 12 weeks
- At least one measurable tumor lesion based on RECIST v1.1
You will not qualify if you...
- History of severe allergic disease, severe drug allergy, or allergy to any study drug components
- Previous treatment with Paclitaxel, Topotecan, or anti-vascular endothelial growth factor (VEGF) drugs
- Severe superior vena cava syndrome or spinal cord compression currently present
- Adverse events from prior anti-tumor therapies not resolved to Grade 1 or lower
- Significant clotting disorders or bleeding risks
- Severe, uncontrollable, or active cardiovascular disease within last 6 months
- Uncontrollable pleural, pericardial, or peritoneal effusions currently present
- HIV infection or AIDS
- History of allogeneic hematopoietic stem cell or organ transplantation
- History of alcohol, psychotropic substance, or drug abuse
- Pregnant or breastfeeding women
- Other conditions deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 45 locations
1
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Not Yet Recruiting
2
Jilin Cancer Hospital
Changchun, Jilin, China
Actively Recruiting
3
The First Affiliated Hospital Of Ningbo University
Ningbo, Zhejiang, China
Not Yet Recruiting
4
Binzhou Medical University Hospital
Binzhou, China
Not Yet Recruiting
5
Hunan Cancer Hospital
Changsha, China
Not Yet Recruiting
6
Sichuan Cancer Hospital
Chengdu, China
Actively Recruiting
7
First People's Hospital of Chenzhou
Chenzhou, China
Not Yet Recruiting
8
The First Affiliated Hospital of Army Medical University
Chongqing, China
Not Yet Recruiting
9
The Second Hospital of Dalian Medical University
Dalian, China
Not Yet Recruiting
10
The First People's Hospital of Foshan
Foshan, China
Not Yet Recruiting
11
Fujian Cancer Hospital
Fuzhou, China
Actively Recruiting
12
The Affiliated Hospital Of Guilin Medical University
Guilin, China
Not Yet Recruiting
13
Zhejiang Cancer Hospital
Hangzhou, China
Not Yet Recruiting
14
Harbin Medical University Cancer Hospital
Harbin, China
Not Yet Recruiting
15
Anhui Province Hospital
Hefei, China
Not Yet Recruiting
16
Shandong Cancer Institute
Jinan, China
Not Yet Recruiting
17
Jingzhou First People's Hospital
Jingzhou, China
Actively Recruiting
18
Affiliated Hospital of Jining Medical University
Jining, China
Not Yet Recruiting
19
Yunnan Cancer Hospital
Kunming, China
Actively Recruiting
20
Liuzhou People's Hospital
Liuzhou, China
Not Yet Recruiting
21
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, China
Not Yet Recruiting
22
Meizhou People's Hospital
Meizhou, China
Not Yet Recruiting
23
Mianyang Central Hospital
Mianyang, China
Not Yet Recruiting
24
Jiangxi Cancer Hospital
Nanchang, China
Not Yet Recruiting
25
The First Affiliated Hospital of Nanchang University
Nanchang, China
Not Yet Recruiting
26
Nanchong Central Hospital
Nanchong, China
Not Yet Recruiting
27
Jiangsu Province Hospital
Nanjing, China
Not Yet Recruiting
28
Nanjing Drum-Tower Hospital
Nanjing, China
Not Yet Recruiting
29
Guangxi Medical University Cancer Hospital
Nanning, China
Not Yet Recruiting
30
Nanyang Central Hospital
Nanyang, China
Not Yet Recruiting
31
Qujing NO.1 Hospital
Qujing, China
Not Yet Recruiting
32
The Fourth Hospital of Hebei Medical University
Shijia Zhuang, China
Not Yet Recruiting
33
Taizhou Enze Medical Center (group)
Taizhou, China
Not Yet Recruiting
34
Weifang NO.2 People's Hospital
Weifang, China
Not Yet Recruiting
35
Weihai Municipal Hospital
Weihai, China
Not Yet Recruiting
36
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Not Yet Recruiting
37
Zhongnan Hospital Of Wuhan University
Wuhan, China
Not Yet Recruiting
38
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Not Yet Recruiting
39
Xiangyang Central Hospital
Xiangyang, China
Actively Recruiting
40
Xuzhou Central Hospital
Xuzhou, China
Not Yet Recruiting
41
The Second People's Hospital Of Yibin
Yibin, China
Not Yet Recruiting
42
Yongzhou Central Hospital
Yongzhou, China
Not Yet Recruiting
43
Yuncheng City Center Hospital
Yuncheng, China
Not Yet Recruiting
44
Zhangzhou Municipal Hospital of Fujian Province
Zhangzhou, China
Not Yet Recruiting
45
Zhoukou Central Hospital
Zhoukou, China
Not Yet Recruiting
Research Team
J
Jia Song
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here